Dehydrozingerone for Health & Longevity - Quick Reference Sheet

Dehydrozingerone for Health & Longevity

Created on 06/14/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Dehydrozingerone is a ginger-derived compound, half of curcumin, that dissolves in water far better. Lab and animal work suggests it neutralizes cell-damaging molecules, calms inflammation, and helps the body handle blood sugar, with early hints for brain and mood. But no human studies of any kind exist — no safety, no dosing. Best viewed today as a research compound. (Full Review)

Protocol

Dose
400–600 mg
Illustrative commercial ingredient dose; no clinically validated human dose exists
Schedule
Twice daily
Short animal plasma residence argues for split dosing to maintain exposure
Timing
With meals
Not established; metabolic animal studies dosed with feeding, so dosing around meals is plausible
Time to effect
Metabolic & anti-inflammatory effects
Days to weeks
Unknown in humans; animal effects developed over days to weeks of dosing

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Children
  • Hormone-sensitive conditions
  • Narrow-therapeutic-index medications
  • Scheduled surgery
Key Interactions
  • P-glycoprotein / ABC-transporter substrates (digoxin, vincristine, some immunosuppressants)
  • Antioxidant/anti-inflammatory OTC products (high-dose ginger extract, curcumin, NSAIDs)
  • Phenolic antioxidant supplements (curcumin, whole ginger)
  • Blood-glucose-lowering supplements (berberine, alpha-lipoic acid)
  • Anticoagulant or antiplatelet therapy

Risk & Side Effects

  • High:
  • Medium:
  • Low: Absence of human safety data; pro-oxidant activity at higher exposures
  • Speculative: Reproductive and hormonal effects; theoretical drug-interaction and efflux-pump effects; allergic or idiosyncratic reactions

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks the proposed glucose-lowering effect
HbA1c < 5.4% Captures sustained glycemic effect
Fasting insulin 2–5 µIU/mL Reflects insulin-sensitizing (AMPK) rationale
hs-CRP < 1.0 mg/L Monitors the anti-inflammatory rationale
ALT/AST ALT < 25 U/L (M), < 22 U/L (F) Surveillance for any hepatic effect of an uncharacterized compound
eGFR / creatinine eGFR > 90 mL/min/1.73m² Kidney is the main distribution/excretion site

Cadence: Baseline, at roughly 8–12 weeks, then every 6–12 months

Qualitative Assessment

  • Energy levels and exercise tolerance
  • Mood and sense of well-being
  • Subjective inflammatory symptoms (e.g., joint comfort)
  • Any new or unexpected symptoms